Gabelli Healthcare & WellnessRx Trust 8-K

What Happened

• The fund disclosed that Mario J. Gabelli, Trustee, Chairman and Chief Investment Officer of the Fund, was hospitalized for observation and testing after a medical incident on March 19, 2026; he was admitted on March 23, 2026. His condition is improving but no return date is known.
• On March 22, 2026, GAMCO (the parent of the Fund’s adviser) implemented a long-standing succession plan. Christopher J. Marangi was named President of GAMCO and, together with co-CEO Douglas R. Jamieson, will lead day-to-day operations during Mr. Gabelli’s absence. The Fund’s portfolio management is being led by Co-Chief Investment Officers Kevin V. Dreyer and Christopher J. Marangi while Mr. Gabelli is away.

Key Details

• Medical incident occurred March 19, 2026; hospital admission noted March 23, 2026.
• Succession plan implemented March 22, 2026; Christopher J. Marangi named President of GAMCO.
• Day-to-day operations led by Douglas R. Jamieson (co-CEO) and Christopher J. Marangi.
• Portfolio management team leadership for the Fund: Kevin V. Dreyer and Christopher J. Marangi during Gabelli’s absence.

Why It Matters

• The filing signals a temporary leadership transition at the adviser level but affirms continuity: established succession procedures were activated and the investment team remains in place.
• For shareholders, this means fund operations and portfolio management are being handled by named successors; the 8-K does not report any financial impact or changes to the Fund’s investment strategy.
• Investors should monitor future filings or press releases for updates on Mr. Gabelli’s health and any further developments in leadership.